Navigation Links
$3.35 Million Awarded in First Transvaginal Mesh Trial Verdict: Prompts McDonaldWorley.com Support Expansion
Date:2/26/2013

Houston, TX (PRWEB) February 26, 2013

The resulting verdict in the nations first pelvic mesh trial has prompted national law firm McDonaldWorley.com to expand the free legal reviews being provided to women who suffered complications. Attorneys with the firm emboldened by the $3.35 million compensation awarded for her past and future pain and suffering, medical costs and lost wages feel claims are strong for women who suffered problems (Gross v. Gynecare Inc., Atl-L-6966-10).

In a 7-2 vote a New Jersey state jury has dealt a blow to manufacturer Johnson & Johnson and its subsidiary in the first case to go to trial.

The jury in the landmark Atlantic City Superior Court case decided Feb. 25, according to HarrisMartin.com, found that the implanting surgeon for the plaintiff, Linda Gross, did not adequately warn of the risks associated with implanting the mesh and that the device was the proximate cause of injury. The judge is conducting a hearing to determine whether she will allow an award for punitive damages.

"The verdict signals to other women that suffered problems that they are not alone, that their needs will not be ignored. It's vital women contact us now to get their questions answered," stated Michelle R. Eddington, lead attorney with the firm.

In addition to helping people understand their legal options, the firm can help victims get funding for revision surgery to remove and repair damage caused if they don't have insurance or other means to pay for the surgery. Women are encouraged to ask for more information about financing options for corrective surgery.

The use of synthetic mesh for repair surgeries has been under scrutiny over the last three years. The FDA, having receiving thousands of reports of adverse effects, issued a health advisory warning in October 2008 to physicians considering transvaginal repair surgeries for their patients.

Dr. Margolis was quoted recently in CommonHealth.org as telling the FDA advisory panel that the use of these implants, "defies core surgical doctrines." and further mesh used in tissue repair procedures has been associated with a number of serious risks including wandering, erosion, infection, pain and perforations.

"Women should know that they are not alone, and that we are standing-by ready to ensure their needs are not ignored," added Ms. Eddington.

About McDonaldWorley.com:
Case evaluations are completely secure, 100% confidential, and being offered for women who have had surgical mesh surgery or family members.

To get information and answers from a real lawyer, click here: http://www.mcdonaldworley.com/transvaginal-mesh-lawyer.htm

Read the full story at http://www.prweb.com/releases/2013/2/prweb10467889.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. NYU Langone Medical Center receives $17 million gift from the Steven A. and Alexandra M. Cohen Foundation
2. NIH awards $12.4 million grant to fund Henry Ford Hospital hypertension research
3. RWJF awards $1.9 million grant to PatientsLikeMe to create open research platform
4. Solid State (Smart) Transformer Market is expected to reach $5,043.39 million at a CAGR of 82.3% by 2020 - New Report by MarketsandMarkets
5. WUSTL researcher gets $2.25 million grant to better understand traumatic brain injury
6. NAS receives $3.5 million gift to establish Prize in Psychological and Cognitive Sciences
7. Dr. Lewis Cantley awarded $3 million breakthrough prize in life sciences
8. UC San Diego cancer scientist wins $3 million award
9. Flame Retardant Chemicals Market growing at a CAGR of 6.9% & to reach $7,131.9 Million by 2017 - New Report by MarketsandMarkets
10. Millions of Americans Have an STD: Report
11. Chris Guedri, of the Law Firm of Allen & Allen, Wins Case Against Food Lion and Ties for Largest Verdict in Gloucester County History: $5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: